Organogenesis stock last at USD 1.00 on October 16, down 9.91 percent
Published on 10/17/2026 at 18:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStock falls 9.91 percent on Nasdaq
- Organogenesis stock fell 9.91 percent on October 16, 2026.
- Third-quarter results are scheduled for November 5, 2026.
- Organogenesis stock last stood at USD 1.00 on October 16, 2026 at 4:00 p.m. ET, 9.91 percent below the prior close of USD 1.11.
- The two-rating consensus cited by DirectorsTalk set a USD 2.00 target on October 16, 2026.
Organogenesis stock last stood at USD 1.00 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 9.91 percent from the USD 1.11 prior close. The next scheduled result is the third-quarter report on November 5, 2026, according to Organogenesis.
Results date sets the next marker
The November 5 date gives investors a defined checkpoint after a difficult second quarter. Organogenesis reported USD 43.76 million in second-quarter 2026 revenue and a USD 99.34 million net loss, according to Quiver Quant. Revenue was 56.68 percent below the same quarter a year earlier, making the upcoming report a test of whether the decline has stabilized.
Price position remains demanding
The Nasdaq price was USD 1.00 at the last timestamp, while the session range ran from USD 0.99 to USD 1.13. Volume reached 1,266,362 shares against an average of 757,056, or 67.28 percent above the average. The 52-week range was USD 0.99 to USD 7.08, placing the last price 85.88 percent below the high and 1.01 percent above the low.
Valuation and analyst view
Organogenesis had a market capitalization of USD 128.6 million and a negative trailing P/E ratio of minus 1.20 on October 16, 2026. DirectorsTalk Interviews reported a two-rating consensus with a USD 2.00 target on October 16, 2026. That target was 100.00 percent above the USD 1.00 last price. The same report described two hold ratings and no sell ratings.
Comparison with peers
ORGO (Nasdaq, USD): minus 9.91 percent, P/E minus 1.20, market capitalization USD 128.6 million.
MiMedx Group (Nasdaq, USD): minus 5.34 percent, P/E 110.75, market capitalization USD 645.7 million.
Integra LifeSciences (Nasdaq, USD): minus 2.37 percent, P/E minus 142.66, market capitalization USD 1.0 billion.
Price and calendar
The November 5, 2026 reporting date is the next scheduled corporate event. Organogenesis operates in regenerative medicine, with products serving advanced wound care, surgical and sports medicine markets.
Nasdaq close sets the frame
Organogenesis stock last stood at USD 1.00 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 9.91 percent versus the prior close of USD 1.11. Its USD 0.99 low and USD 7.08 high show how close the latest price is to the bottom of its yearly range.
Market context: Market report Nasdaq Composite.
